Organon &

Organon & ROA

The Return on Assets (ROA) of Organon & (OGN) as of Nov 11, 2026 is 1.45 %. In the previous year, Return on Assets (ROA) was 6.59 % — a change of -77.96% (lower).

ROA

1.45 %

YoY

-77.96%

Last updated:

In 2025, Organon &'s return on assets (ROA) was 1.45 %, a -77.96% increase from the 6.59 % ROA in the previous year.

The Organon & ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
20.52 USD
Jan 1, 2019
30.51 USD
Jan 1, 2020
21.37 USD
Jan 1, 2021
12.65 USD
Jan 1, 2022
8.37 USD
Jan 1, 2023
8.48 USD
Jan 1, 2024
6.59 USD
Jan 1, 2025
1.45 USD
The Organon & ROA history
YEARROAYoY
1.45 %-77.96%
6.59 %-22.27%
8.48 %+1.35%
8.37 %-33.82%
12.65 %-40.80%
21.37 %-29.96%
30.51 %+48.70%
20.52 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Organon & Stock analysis

What does Organon & do? Organon & Co. generates revenue through prescription therapies and medical devices focused on women’s health, biosimilars, and established brands. Key products include contraception and fertility solutions like Nexplanon, Implanon NXT, NuvaRing, Follistim AQ, and Elonva, alongside biosimilars for immunology and oncology. Established brands cover cardiovascular, respiratory, dermatology, and non-opioid pain management segments. The company sells directly to drug wholesalers, retailers, hospitals, government agencies, and managed healthcare providers such as health maintenance organizations and pharmacy benefit managers. Organon’s portfolio targets healthcare institutions and providers, with products distributed through established pharmaceutical channels. The company’s biosimilars and women’s health brands drive sales in specialized medical markets, while established brands serve broader therapeutic areas. Revenue streams are derived from direct sales to healthcare systems and institutions that manage patient care across multiple therapeutic categories. The firm’s strategy centers on delivering innovative health solutions via a diversified product portfolio. Prescription therapies for women’s health, including contraceptive and fertility treatments, form a significant segment of sales. Biosimilars in immunology and oncology, alongside established brands in cardiovascular and respiratory care, contribute to recurring revenue from institutional buyers. Organon & is one of the most popular companies on Eulerpool.

ROA Details

Understanding Organon &'s Return on Assets (ROA)

Organon &'s Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Organon &'s ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Organon &'s ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Organon &’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Organon & stock

Return on Assets (ROA) of Organon & is 1.45 % in 2025.

Return on Assets (ROA) of Organon & changed from 6.59 % to 1.45 %, representing a -77.96% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Organon & since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Organon & with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Organon &

All Key Metrics — Organon &